139705-74-1

Basic information

• Product Name: 4-IMIDAZO[1,2-A]PYRIDIN-2-YL-PHENYLAMINE
• Synonyms: 4-IMIDAZO[1,2-A]PYRIDIN-2-YLANILINE;4-IMIDAZO[1,2-A]PYRIDIN-2-YL-PHENYLAMINE;IFLAB-BB F1912-0016;2-(4-Aminophenyl)imidazo[1,2-a]pyridine;4-(IMidazo[1,2-a]pyrid-2-yl)aniline, 95%
• CAS NO: 139705-74-1
• Molecular Formula: C₁₃H₁₁N₃
• Molecular Weight: 209.25
• Mol File: 139705-74-1.mol
• Article Data: 9

Chemical Properties

• Melting Point: 204-206°
• Appearance: /
• Density: 1.24 g/cm³
• Refractive Index: 1.68
• Storage Temp.: 2-8°C
• PKA: 6.97±0.50(Predicted)
• CAS DataBase Reference: 4-IMIDAZO[1,2-A]PYRIDIN-2-YL-PHENYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-IMIDAZO[1,2-A]PYRIDIN-2-YL-PHENYLAMINE(139705-74-1)
• EPA Substance Registry System: 4-IMIDAZO[1,2-A]PYRIDIN-2-YL-PHENYLAMINE(139705-74-1)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 139705-74-1(Hazardous Substances Data)

Usage

Description

4-IMIDAZO[1,2-A]PYRIDIN-2-YL-PHENYLAMINE is an organic compound that serves as a crucial intermediate in the synthesis of various pharmaceuticals. It is characterized by its unique chemical structure, which includes an imidazopyridine ring fused with a phenylamine group. This structure endows it with specific properties that make it valuable in the development of new drugs.

Uses

Used in Pharmaceutical Industry:
4-IMIDAZO[1,2-A]PYRIDIN-2-YL-PHENYLAMINE is used as an intermediate for the preparation of new imidazopyridines. These imidazopyridines are developed as angiotensin antagonists, which possess antihypertensive activity. By targeting the renin-angiotensin system, these compounds can effectively manage high blood pressure and contribute to the treatment of hypertension.
As an intermediate, 4-IMIDAZO[1,2-A]PYRIDIN-2-YL-PHENYLAMINE plays a vital role in the synthesis of these angiotensin antagonists, enabling the development of novel therapeutic agents to combat hypertension and its associated health risks.

InChI:InChI=1/C13H11N3/c14-11-6-4-10(5-7-11)12-9-16-8-2-1-3-13(16)15-12/h1-9H,14H2

Upstream product

• 112581-95-0 2-Bromoimidazo[1,2-a]pyridine 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 
• 504-29-0 2-aminopyridine 
• 99-81-0 4-Nitrophenacyl bromide 
• 3323-26-0 2-(4-nitrophenyl)imidazo[1,2-a]pyridine 

Downstream Products

• 1291779-70-8 N-(4-(imidazo[1,2-a]pyridin-2-yl)-phenyl)-2,2,2-trifluoroacetamide 
• 1291779-71-9 N-(4-(imidazo[1,2-a]pyridin-2-yl)-phenyl)-N-methyl-2,2,2-trifluoroacetamide 
• 1291779-97-9 (1R,3S)-3-propionylamino-cyclopentanecarboxylic acid N-[4-(imidazo[1,2-a]pyridin-2-yl)phenyl]-N-methyl-amide 
• 312623-35-1 N-(4-(Imidazo[1,2-a]pyridin-2-yl)phenyl)-3-methoxybenzamide 
• 372096-35-0 N-[4-(Imidazo[1,2-a]pyridin-2-yl)phenyl]-(2-chloro-5-nitrophenyl)carboxamide 
• 497848-13-2 4-(indolizin-2-yl)-N-methylbenzeneamine 
• 14954-72-4 2-(4′-dimethylaminophenyl)-6-imidazo[1,2-a]pyridine 
• 118000-46-7 N-(4-Imidazo[1,2-a]pyridin-2-yl-phenyl)-benzenesulfonamide 
• 139705-76-3 1-(4-Imidazo[1,2-a]pyridin-2-yl-phenylamino)-3-(2-nitro-imidazol-1-yl)-propan-2-ol 
• 103823-85-4 N-(4-imidazo[1,2-a]pyridin-2-yl-phenyl)-acetamide 
• 799257-56-0 N-acetyl-sulfanilic acid-(4-imidazo[1,2-a]pyridin-2-yl-anilide) 

Relevant articles and documents

READ-THROUGH INDUCER AND PHARMACEUTICAL USE THEREOF

PROBLEM TO BE SOLVED: To provide a novel read-through inducer. SOLUTION: The present invention relates to a compound represented by the general formula (I) [each symbol in the formula is as described in the specification] or a pharmaceutically acceptable

Discovery of novel N-(5-(tert-butyl)isoxazol-3-yl)-N′-phenylurea analogs as potent FLT3 inhibitors and evaluation of their activity against acute myeloid leukemia in vitro and in vivo

FLT3 inhibitors have been explored as a viable therapy for acute myeloid leukemia (AML). However, the clinical outcomes of these FLT3 inhibitors were underwhelming except AC220. Therefore, the development of novel FLT3 inhibitors with high potency against

HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM

The invention relates to novel heterocyclic compounds and to the use thereof, to pharmaceutical compositions containing said chemical compounds as an active ingredient and to the use thereof for producing medicinal preparations for the human being and warm-blood animals for treating diseases caused by the aberrant activity of an Hedgehog (Hh)-signal system, in particular oncological diseases. The invention also relates to the use of the above-mentioned compounds in the form of ‘molecular pharmacological tools’ for examining (in vitro and in vivo) the biochemical features of the Hh-signal system, in particular, the interaction of Hh protein and transmembrane proteins, namely, suppressor Patched (Ptc) and protooncogenic proteins. The eight groups of the claimed compounds comprise the derivatives of 2,6-dihydro-7H-pyrazolo[3,4-d]pyridazine-7-one and 1,4-dihydropyrazolo[3,4-b][1,4]thiazine-5-one; N-acidylated 4-imidazo[1,2-a]pyrimidine-2-il-anilines; ([4H-thino[3,2-b]pyrrol-5-il) carbonyl]piperidine-4-carbonic acid amides; 2-(4carbomoilpyperidine-1-il)-isonicotinic acid amides; N-sylphonyl-1,2,3,4-tetrahydroquinoline-6-carbonic acid amides; and pyridine 2-amino-4,5,6,7-tetrahydrothieno[2,3-c] N-acidylated 3-azole derivatives.